MedinCell S.A. (MEB.F)
Frankfurt · EUR · Healthcare · Biotechnology
€25.74 (+0.94%) as of
Key statistics
- Market cap
- 924.60M
- EPS (TTM)
- -0.94
- Dividend yield
- 0.00%
- 52-week range
- 19.49 – 37.82
- Beta
- 0.92
- Revenue (TTM)
- 24.28M
- Profit margin
- -128.88%
- Volume
- 2.00k
About MedinCell S.A.
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Jacou, France
- Employees
- 141
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.